Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 1, Janvier 2007
Page(s) 81 - 87
Section M/S revues
DOI https://doi.org/10.1051/medsci/200723181
Publié en ligne 15 janvier 2007
  1. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart 2003; 89 : 801–5.
  2. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111 : 3316–26.
  3. Otto CM, O’Brien KD. Why is there discordance between calcific aortic stenosis and coronary artery disease ? Heart 2001; 85 : 601–2.
  4. Chan KL. Is aortic stenosis a preventable disease ? J Am Coll Cardiol 2003; 42 : 593–9.
  5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 : 1415–28.
  6. Junquero D, Rival Y. Syndrome métabolique : quelle définition pour quels traitements ? Med Sci (Paris) 2005; 21 : 1045–53.
  7. Drolet MC, Roussel E, Deshaies Y, et al. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 2006; 47 : 850–5.
  8. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47 : 2229–37.
  9. Després JP. Inflammation and cardiovascular disease: is abdominal obesity the missing link ? Int J Obes Relat Metab Disord 2003; 27 (suppl 3) : S22–4.
  10. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6 : 13–21.
  11. Briand M, Pibarot P, Despres JP, et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006; 114 (suppl 1) : I512–7.
  12. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40 : 1723–30.
  13. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110 : 1291–5.
  14. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352 : 2389–97.
  15. Novaro GM, Sachar R, Pearce GL, et al. Association between apolipoprotein e alleles and calcific valvular heart disease. Circulation 2003; 108 : 1804–8.
  16. Ortlepp JR, Hoffmann R, Ohme F, et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001; 85 : 635–8.
  17. Garg V, Muth AN, Ransom JF, et al. Mutations in Notch1 cause aortic valve disease. Nature 2005; 437 : 270–4.
  18. Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44 : 138–43.
  19. Bonow RO, Carabello BA, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guide. Circulation 2006; 114 : 84–231.
  20. Garcia D, Pibarot P, Dumesnil JG, et al. Assessment of aortic valve stenosis severity: A new index based on the energy loss concept. Circulation 2000; 101 : 765–71.
  21. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly LV afterload and functions in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005; 46 : 291–8.
  22. Garcia D, Dumesnil JG, Durand LG, et al. Discrepancies between catheter and Doppler estimates of valve effective orifice area can be predicted from the pressure recovery phenomenon: practical implications with regard to quantification of aortic stenosis severity. J Am Coll Cardiol 2003; 41 : 435–42.
  23. Kadem L, Dumesnil JG, Rieu R, et al. Impact of systemic hypertension on the assessment of aortic stenosis. Heart 2005; 91 : 354–61.
  24. Garcia D, Barenbrug PJ, Pibarot P, et al. A ventricular-vascular coupling model in presence of aortic stenosis. Am J Physiol Heart Circ Physiol 2005; 288 : 1874–84.
  25. Antonini-Canterin F, Huang G, Cervesato E, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role ? Hypertension 2003; 41 : 1268–72.
  26. Blais C, Pibarot P, Dumesnil JG, et al. Comparison of valve resistance with effective orifice area regarding flow dependence. Am J Cardiol 2001; 1 : 45–52.
  27. Blais C, Burwash IG, Mundigler G, et al. The projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low flow aortic stenosis: the multicenter TOPAS (truly or pseudo severe aortic stenosis) study. Circulation 2006; 113 : 711–21.
  28. Monin JL, Quere JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation 2003; 108 : 319–24.
  29. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart 2005; 92 : 1022–9.
  30. Blais C, Dumesnil JG, Baillot R, et al. Impact of prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation 2003; 108 : 983–8.
  31. Tasca G, Mhagna Z, Perotti S, et al. Impact of prosthesis-patient mismatch on cardiac events and midterm mortality after aortic valve replacement in patients with pure aortic stenosis. Circulation 2006; 113 : 570–6.
  32. Andelfinger G. La valve aortique n’a pas révélé tous ses secrets. Med Sci (Paris) 2007; 23 : 93–4.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.